Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 13, 2016 (10 years ago)

Dexpanthenol 250mg/Ml W/Pres.

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

DEXPANTHENOL 250MG/ML W/PRES. (BENZALKONIUM CHL 0.01%), 10ML Vials, MEDAUS PHARMACY

Drug: Benzalkonium

Recalling firm
Medaus, Inc.
Origin
AL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1179-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Benzalkonium recalls

See all
Class II · Moderate risk

Revitaderm Wound Care

CGMP Deviations; product manufactured in the same facility under the same conditions as the product found to be contaminated

Ongoing cGMP deviation Blaine Labs Inc NDC 63347-120-02 D-0699-2026
Class I · High risk

Revitaderm Wound Care Gel

Microbial contamination of Non-Sterile Product: samples identified the presence of Lysinibacillus fusiformis and other Bacillus spp

Ongoing Microbial contamination Blaine Labs Inc NDC 63347-120-02 D-0692-2026

Other recalls by Medaus, Inc.

All 2016 recalls